About medincell sa - MDCLF
MedinCell SA is a pharmaceutical company, which engages in the development of injectable products in therapeutic areas. It focuses on combining its proprietary BEPO technology with active ingredients already known and marketed; it controls the regular delivery of a drug at the optimal therapeutic dose. The company was founded by Anh Nguyen and Christophe Douat on January 9, 2003 and is headquartered in Jacou, France.
MDCLF At a Glance
MedinCell SA
3, rue des Frères Lumière
Jacou, Occitanie 34830
| Phone | N/A | Revenue | 22.62M | |
| Industry | Pharmaceuticals: Major | Net Income | -36,252,963.86 | |
| Sector | Health Technology | Employees | 150 | |
| Fiscal Year-end | 03 / 2027 | |||
| View SEC Filings |
MDCLF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 38.319 |
| Price to Book Ratio | 264.144 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -30.441 |
| Enterprise Value to Sales | 36.922 |
| Total Debt to Enterprise Value | 0.079 |
MDCLF Efficiency
| Revenue/Employee | 150,773.026 |
| Income Per Employee | -241,686.426 |
| Receivables Turnover | 1.88 |
| Total Asset Turnover | 0.204 |
MDCLF Liquidity
| Current Ratio | 4.671 |
| Quick Ratio | 4.671 |
| Cash Ratio | 4.095 |
MDCLF Profitability
| Gross Margin | N/A |
| Operating Margin | -130.638 |
| Pretax Margin | -185.014 |
| Net Margin | -160.298 |
| Return on Assets | -32.63 |
| Return on Equity | N/A |
| Return on Total Capital | -52.027 |
| Return on Invested Capital | -69.861 |
MDCLF Capital Structure
| Total Debt to Total Equity | 1,873.76 |
| Total Debt to Total Capital | 94.934 |
| Total Debt to Total Assets | 53.132 |
| Long-Term Debt to Equity | 1,765.96 |
| Long-Term Debt to Total Capital | 89.472 |